End of Gene Patents Will Help Patients, Force Companies to Change

When you went to sleep last Sunday night, 20 percent of your genome belonged to a researcher or company. One day later, following federal district court judge Robert Sweet’s ruling, it belonged to you.

Some activists cheered the landmark decision on general principle, but for others, it was a business and medical matter. They say the end of gene patents could be a boon for patients, who will benefit from gene-testing companies competing for their business.

Read more